Pathologic progression of autochthonous prostate cancer in the TRAMP model

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 2, 1999, Pages 70-75

  Gingrich, J R ^a   Barrios, R J ^b   Foster, B A ^b   Greenberg, N M ^b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c Dept Cell Biol Scott Dept Urol ^*  (United States)

Author keywords

Metastasis; Prostate cancer; Receptor; TRAMP; Transgenic mice

Indexed keywords

ANDROGEN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER GROWTH; FEMALE; GENE EXPRESSION; GENE MUTATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 0033049122     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500296     Document Type: Article

References (21)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. [published erratum appears in CA Cancer J Clin 1998; 48: 192]; CA Cancer J Clin 1998; 48: 6-29.
2. Wheeler TM, Lebovitz RM. Fresh tissue harvest for research from prostatectomy specimens. Prostate 1994; 25: 274-279.
3. Bostwick DG. Prospective origins of prostate carcinoma; Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer 1996; 78: 330-336.
4. Deng G et al. Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 1996; 274: 2057-2059.
5. Westra WH, Sidransky D. Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles [editorial] [In Process Citation]. J Natl Cancer Inst 1998; 90: 1500-1501.
6. Morton RA, Jr. Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994; 44: 637-645.
7. Powell IJ. Prostate cancer and African-American men. Oncology (Huntington) 1997; 11: 599-605; discussion 606-615 passim.
8. Stanford JL et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res 1997; 57: 1194-1198.
9. Gould KA et al. Genetic evaluation of candidate genes for the Mom1 modifier of intestinal neoplasia in mice. Genetics 1996; 144: 1777-1785.
10. Green JE et al. Workgroup 3: transgenic and reconstitution models of prostate cancer. Prostate 1998; 36: 59-63.
11. Greenberg NM et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439-3443.
12. Gingrich JR, Greenberg NM. A transgenic mouse prostate cancer model. Toxicol Path 1996; 24: 502-504.
13. Gingrich JR et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-4102.
14. Gingrich JR et al. Androgen independent prostate cancer progression in the TRAMP model. Cancer Res 1997; 57: 4687-4691.
15. Greenberg NM et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994; 8: 230-239.
16. Foster BA et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330.
17. Prins GS, Birch L. The developmental pattern of androgen receptor expression in rat prostate lobes is altered after neonatal exposure to estrogen. Endocrinology 1995; 136: 1303-1314.
18. Donjacour AA, Rosales A, Higgins SL, Cunha GR. Characterization of antibodies to androgen-dependent secretory proteins of the mouse dorsolateral prostate. Endocrinology 1990; 126: 1343-1354.
19. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991; 129: 3187-3199.
20. Hsu CX et al. Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice. J Urol 1998; 160: 1500-1505.
21. Thompson TC et al. Genetic predisposition and mesenchymal-epithelial interactions in ras + myc-induced carcinogenesis in reconstituted mouse prostate. Mol Carcinog 1993; 7: 165-179.